Celltrion is accelerating the global rollout of its ophthalmic drug Eyedenzelt, securing key markets in the US, Canada, and Europe through strategic patent settlements and differentiated market entry strategies.
#YonhapInfomax #Celltrion #Eyedenzelt #PatentSettlement #GlobalMarket #Aflibercept #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=99424
Celltrion Accelerates Global Market Expansion for Eyedenzelt, Its Ophthalmic Treatment

Celltrion is accelerating the global rollout of its ophthalmic drug Eyedenzelt, securing key markets in the US, Canada, and Europe through strategic patent settlements and differentiated market entry strategies.

Yonhap Infomax
πŸ’ŠπŸ’‰ #aflibercept
SmPC for ZALTRAP 25 mg/ml concentrate for solution for infusion has been updated with changes to sections 10. Date of revision of the text on 20 December 2023.
🌐 https://www.medicines.org.uk/emc/product/2971/smpc
Change log: https://www.medicines.org.uk/emc/product/2971/smpc/history
Zaltrap 25mg/ml concentrate for solution for infusion - Summary of Product Characteristics (SmPC) - (emc)

Zaltrap 25mg/ml concentrate for solution for infusion - Summary of Product Characteristics (SmPC) by SANOFI

πŸ’ŠπŸ’‰ #aflibercept
SmPC for ZALTRAP 25 mg/ml concentrate for solution for infusion has been updated with changes to sections 2. Qualitative and quantitative composition; 4.6 Fertility, pregnancy and lactation; 5.2 Pharmacokinetic properties; 6.5 Nature and contents of container; 10. Date of revision of the text on 01 December 2023.
🌐 https://www.medicines.org.uk/emc/product/2971/smpc
Change log: https://www.medicines.org.uk/emc/product/2971/smpc/history
Zaltrap 25mg/ml concentrate for solution for infusion - Summary of Product Characteristics (SmPC) - (emc)

Zaltrap 25mg/ml concentrate for solution for infusion - Summary of Product Characteristics (SmPC) by SANOFI

Researchers report one drug more effective in treating wet age-related macular degeneration

Researchers say the drug aflibercept performed better in a clinical trial than bevacizumab in helping wean people off treatments for wet age-related macular degeneration

Medical News Today